Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 15:9:843913.
doi: 10.3389/fsurg.2022.843913. eCollection 2022.

Analysis of Clinical Characteristics, Treatment, and Prognostic Factors of 106 Breast Cancer Patients With Solitary Pulmonary Nodules

Lihong He  1 , Xiaorui Wang  1 , Xiaodong Liu  1 , Yongsheng Jia  1 , Weipeng Zhao  1 , Xiaochen Jia  1 , Yuehong Zhu  1 , Wenjing Meng  1 , Zhongsheng Tong  1
Affiliations

Analysis of Clinical Characteristics, Treatment, and Prognostic Factors of 106 Breast Cancer Patients With Solitary Pulmonary Nodules

Lihong He et al. Front Surg. .

Abstract

Objective: The clinical features of solitary pulmonary nodules (SPN) in breast cancer patients were retrospectively analyzed, and the clinical features of primary lung cancer (PLC) and metastatic pulmonary breast cancer (MBC) in breast cancer patients were compared, and the treatment plan, curative effect and influencing factors were analyzed.

Methods: The clinical data of 106 patients of SPN combined with breast cancer surgery in our hospital from January 2015 to June 2020 were analyzed. There were 65 patients of PLC and 41 patients of MBC. Record the characteristics of the primary breast cancer lesion in our patient, the interval between the initial diagnosis of breast cancer and the appearance of SPN, the previous treatment history of our patient, and the characteristics and surgical method of SPN. The survival status of all patients during the follow-up period was recorded.

Results: The onset age, interval, maximum nodule diameter, ER expression positive rate and radiotherapy history ratio of PLC patients were higher than those of MBC patients, and the lymph node positive rate and triple negative rate were lower than those of MBC patients (P < 0.05). Median survival was 51 months in patients with PLC and 37 months in patients with MBC. The 1, 3, and 5 year overall survival rates in patients with PLC were higher than those in patients with MBC (P < 0.05). Vascular tumor thrombus, SPN type and chemotherapy were all independent factors affecting the prognosis of patients with breast cancer combined with SPN (P < 0.05).

Conclusion: PLC patients and MBC patients have significant differences in pathological characteristics, like the onset age, interval, maximum nodule diameter, ER expression positive rate, radiotherapy history ratio, the lymph node positive rate, and triple negative rate. Septum, vascular tumor thrombus, SPN type, and chemotherapy are all independent factors that affect the curative effect of breast cancer patients with SPN. Based on the nature of SPN, it can provide reference for clinicians to decide the treatment plan, improve patients' quality of life and prolong their survival time.

Keywords: breast cancer; metastatic pulmonary breast cancer; primary lung cancer; prognosis; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Patient survival curves of PLC and MBC.
See this image and copyright information in PMC

References

    1. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol. (2020) 27:27–35. 10.1097/PAP.0000000000000232 - DOI - PubMed
    1. Cai WL, Greer CB, Chen JF, Arnal-Estapé A, Cao J, Yan Q, et al. . Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain. BMC Med Genomics. (2020) 13:33. 10.1186/s12920-020-0695-0 - DOI - PMC - PubMed
    1. Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast cancer lung metastasis: Molecular biology and therapeutic implications. Cancer Biol Ther. (2018) 19:858–68. 10.1080/15384047.2018.1456599 - DOI - PMC - PubMed
    1. Medeiros B, Allan AL. Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int J Mol Sci. (2019) 20:2272. 10.3390/ijms20092272 - DOI - PMC - PubMed
    1. Peart O. Metastatic breast cancer. Radiol Technol. (2017) 88:519–39. - PubMed

LinkOut - more resources